Peter J. Boerrigter

827 total citations · 1 hit paper
13 papers, 661 citations indexed

About

Peter J. Boerrigter is a scholar working on Urology, Endocrinology, Diabetes and Metabolism and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Peter J. Boerrigter has authored 13 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Urology, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Peter J. Boerrigter's work include Urinary Bladder and Prostate Research (6 papers), Ovarian function and disorders (4 papers) and Estrogen and related hormone effects (3 papers). Peter J. Boerrigter is often cited by papers focused on Urinary Bladder and Prostate Research (6 papers), Ovarian function and disorders (4 papers) and Estrogen and related hormone effects (3 papers). Peter J. Boerrigter collaborates with scholars based in Netherlands, United Kingdom and France. Peter J. Boerrigter's co-authors include Christopher R. Chapple, Ted Drogendijk, M. Wooning, J. Cambronero, J.C. Angulo, Vik Khullar, G. Amarenco, Tomasz Rechberger, Piotr Radziszewski and Ian Milsom and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Human Reproduction and European Urology.

In The Last Decade

Peter J. Boerrigter

12 papers receiving 635 citations

Hit Papers

Efficacy and Tolerability of Mirabegron, a β3-Adrenocepto... 2012 2026 2016 2021 2012 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
    2012 329 citations Vik Khullar, G. Amarenco et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter J. Boerrigter Netherlands 10 482 348 290 96 92 13 661
Jukka Sairanen Finland 11 830 1.7× 552 1.6× 390 1.3× 37 0.4× 35 0.4× 22 947
M. Holm‐Bentzen Denmark 13 405 0.8× 160 0.5× 203 0.7× 13 0.1× 34 0.4× 30 545
L Simon United States 9 391 0.8× 272 0.8× 234 0.8× 17 0.2× 24 0.3× 16 513
Sang Jin Yoon South Korea 13 272 0.6× 190 0.5× 79 0.3× 11 0.1× 45 0.5× 43 430
Päivi Rahkola‐Soisalo Finland 14 83 0.2× 275 0.8× 82 0.3× 28 0.3× 84 0.9× 37 517
Richard P. Santarosa United States 10 327 0.7× 275 0.8× 47 0.2× 10 0.1× 42 0.5× 16 490
Shih‐Cheng Hsu Taiwan 10 101 0.2× 185 0.5× 56 0.2× 100 1.0× 95 1.0× 20 390
Thomas Laml Austria 12 52 0.1× 71 0.2× 51 0.2× 116 1.2× 76 0.8× 25 438
Ayush Giri United States 13 29 0.1× 199 0.6× 94 0.3× 33 0.3× 63 0.7× 34 551
Zhenli Gao China 13 157 0.3× 72 0.2× 51 0.2× 5 0.1× 47 0.5× 40 431

Countries citing papers authored by Peter J. Boerrigter

Since Specialization
Citations

This map shows the geographic impact of Peter J. Boerrigter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Boerrigter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Boerrigter more than expected).

Fields of papers citing papers by Peter J. Boerrigter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Boerrigter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Boerrigter. The network helps show where Peter J. Boerrigter may publish in the future.

Co-authorship network of co-authors of Peter J. Boerrigter

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Boerrigter. A scholar is included among the top collaborators of Peter J. Boerrigter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Boerrigter. Peter J. Boerrigter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Chapple, Christopher R., Vladimír Dvořák, Philip Van Kerrebroeck, et al.. (2013). A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal. 24(9). 1447–1458. 107 indexed citations
2.
Νitti, Victor W., Sender Herschorn, Stephen M. Auerbach, et al.. (2012). The Potent and Selective Beta3-adrenoceptor Agonist Mirabegron Improves Patient-reported Outcomes in Overactive Bladder–Results from Two Phase III Studies. Neurourology and Urodynamics. 1 indexed citations
3.
Khullar, Vik, G. Amarenco, J.C. Angulo, et al.. (2012). Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial. European Urology. 63(2). 283–295. 329 indexed citations breakdown →
4.
Khullar, Vik, et al.. (2011). The efficacy and tolerability of mirabegron, a potent and selective ß3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder – results from a European–Australian Phase III trial. 4 indexed citations
5.
Khullar, V., J. Cambronero, Peter Ströberg, et al.. (2011). 886 THE EFFICACY AND TOLERABILITY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER – RESULTS FROM A EUROPEAN–AUSTRALIAN PHASE III TRIAL. European Urology Supplements. 10(2). 278–279. 34 indexed citations
6.
Chapple, Christopher R., et al.. (2010). 774 DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB). European Urology Supplements. 9(2). 249–249. 41 indexed citations
7.
Escudero, Ernesto, Peter J. Boerrigter, Herjan J.T. Coelingh Bennink, et al.. (2005). Mifepristone Is an Effective Oral Alternative for the Prevention of Premature Luteinizing Hormone Surges and/or Premature Luteinization in Women Undergoing Controlled Ovarian Hyperstimulation forin VitroFertilization. The Journal of Clinical Endocrinology & Metabolism. 90(4). 2081–2088. 20 indexed citations
8.
Bennink, Herjan J.T. Coelingh & Peter J. Boerrigter. (2003). Use of dydrogesterone as a progestogen for oral contraception. Steroids. 68(10-13). 927–929. 6 indexed citations
9.
Beckers, Nicole G.M., Nicholas S. Macklon, Paul Devroey, et al.. (2003). First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertility and Sterility. 79(3). 621–623. 40 indexed citations
10.
Boerrigter, Peter J.. (2002). Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix. Human Reproduction. 17(8). 2027–2034. 27 indexed citations
11.
Boerrigter, Peter J., Herman Ellman, & Michael Dolker. (1999). International clinical experience with a new low-dose, Monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg. Clinical Therapeutics. 21(1). 118–127. 17 indexed citations
12.
Boerrigter, Peter J., P. H. M. van de Weijer, Jan P. A. Baak, et al.. (1996). Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas. 24(1-2). 63–71. 21 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jukka Sairanen Breakdown of academic impact, for papers by M. Holm‐Bentzen Breakdown of academic impact, for papers by L Simon Breakdown of academic impact, for papers by Sang Jin Yoon Breakdown of academic impact, for papers by Päivi Rahkola‐Soisalo Breakdown of academic impact, for papers by Richard P. Santarosa Breakdown of academic impact, for papers by Shih‐Cheng Hsu Breakdown of academic impact, for papers by Thomas Laml Breakdown of academic impact, for papers by Ayush Giri Breakdown of academic impact, for papers by Zhenli Gao
Rankless by CCL
2026